Brenmiller Energy to Localize Manufacturing of bGen™ Thermal Energy Batteries to Capitalize on Commercial Opportunities in Europe and the U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2025
0mins
Source: Newsfilter
Brenmiller's Strategic Shift: Brenmiller Energy has decided to forgo a €3.5 million funding commitment from the European Investment Bank to focus on establishing localized manufacturing facilities in Europe and the U.S., aiming to enhance profit margins and reduce logistics costs.
Gigafactory Success: The company's gigafactory in Israel, funded by an initial €4 million, is now fully operational with a capacity of 1 GWh annually, potentially scaling to 4 GWh, supporting a project pipeline valued at over $500 million and generating significant revenue opportunities in both European and U.S. markets.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on BNRG
About BNRG
Brenmiller Energy Ltd is an Israel-based company, which provides sustainable thermal energy storage solutions. The Company's technology bGen is a patented high-temperature thermal energy storage unit stored in solid state material enables the storage of energy generated from different renewable sources: electrical, such as photovoltaic, wind, or grid at off-peak; Thermal sources such as biomass, flue-gas, and deliver steam or hot air on demand. The Company has developed a number of products on the basis of its bGen technology, which it markets to players in the field of power plants and industry, and commercial facilities which consume thermal energy in significant quantities for the purpose of their activity to reduction emission.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Brenmiller Energy (BNRG) to Implement 7-for-1 Reverse Split on January 23, 2026
- Reverse Split Announcement: Brenmiller Energy has announced a 7-for-1 reverse split effective after market close on January 23, 2026, reducing its outstanding shares from approximately 5.01 million to about 716,000, which aims to increase the share price and attract more investor interest.
- Shareholder Approval: The reverse split plan was approved by shareholders on January 13, reflecting confidence in the company's future and providing support for its continued listing on the Nasdaq Capital Market.
- Trading Schedule: The company's shares are expected to begin trading on a post-split basis on January 26, 2026, under the same ticker symbol BNRG, ensuring convenience for investors during the transition.
- Authorized Capital Unchanged: Despite the significant reduction in outstanding shares, the company's authorized share capital will remain unchanged, indicating that Brenmiller retains the capacity for future financing or equity adjustments to support its business growth.
Continue Reading
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Continue Reading